Molecular Templates Inc (MTEM) Files 10-K for the Fiscal Year Ended on December 31, 2017

Molecular Templates Inc (NASDAQ:MTEM) files its latest 10-K with SEC for the fiscal year ended on December 31, 2017. Molecular Templates Inc is a clinical-stage biopharmaceutical company. It develops next generation immunotoxins known as Engineered Toxin Bodies for the treatment of individuals living with various cancer. Molecular Templates Inc has a market cap of $215.160 million; its shares were traded at around $8.00 with and P/S ratio of 30.53.

For the last quarter Molecular Templates Inc reported a revenue of $0.82 million, compared with the revenue of $-1.53 million during the same period a year ago. For the latest fiscal year the company reported a revenue of $3.40 million, an increase of -100% from last year. For the last five years Molecular Templates Inc had an average revenue decline of 0% a year.

The reported loss per diluted share was $2.11 for the year, an increase of -43.6% from previous year. The Molecular Templates Inc had an operating margin of -525.68%, compared with the operating margin of 0% a year before. The 10-year historical median operating margin of Molecular Templates Inc is -340.87%. The profitability rank of the company is 3 (out of 10).

At the end of the fiscal year, Molecular Templates Inc has the cash and cash equivalents of $58.9 million, compared with $10.6 million in the previous year. The long term debt was $1.08 million. The interest coverage to the debt is at a comfortable level of 16.7. Molecular Templates Inc has a financial strength rank of 6 (out of 10).

At the current stock price of $8.00, Molecular Templates Inc is traded at 34.5% premium to its historical median P/S valuation band of $5.95. The P/S ratio of the stock is 30.53, while the historical median P/S ratio is 22.72. The stock gained 27.59% during the past 12 months.

For the complete 20-year historical financial data of MTEM, click here.

Leave a Reply

Your email address will not be published. Required fields are marked *